Compare Enovix Corporation (ENVX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Illumina, Inc. — how do they compare? Enovix Corporation trades at $4.86 (market cap $1.01B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is far larger — about 28.7× Enovix Corporation's market cap, and Illumina, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | ILMN | |
|---|---|---|
Market Cap | $1.01B | $28.96B |
Sector | Technology | Health |
52-Week High | $13.19 | $205.10 |
52-Week Low | $3.68 | $91.00 |
Enterprise Value | $1.03B | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.70, up 10.33% today, with a bullish technical signal despite negative profitability. Recent earnings beats and a $12.38 consensus price target suggest upside potential. The company is ramping production of advanced silicon-anode batteries, with key developments including a new COO appointment and upcoming Q2 2026 results on August 12, 2026.
Outlook remains speculative with high revenue growth potential but persistent losses; risks include cash burn and competitive pressures. Analyst sentiment is positive (75% buy ratings), but investors should weigh the long-term growth story against near-term financial challenges.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
